FDA Receives Biologics License Application for Etentamig in Relapsed/Refractory Multiple Myeloma

AbbVie has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig (ABBV-383), an investigational second-generation BCMA x CD3 bispecific antibody T-cell engager. The application seeks approval for the treatment of adult patients with relapsed/refractory multiple myeloma, supported by positive data from the Phase 3 CERVINO trial, which met its dual primary endpoints of overall response rate and progression-free survival.

Context

Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. Patients with relapsed or refractory multiple myeloma have limited treatment options, making new therapies crucial. AbbVie's etentamig is a bispecific antibody designed to engage T-cells to target cancer cells, representing a novel approach in this therapeutic area. The Phase 3 CERVINO trial provided promising results, which support the application for FDA approval.

Why it matters

The FDA's review of the Biologics License Application for etentamig is significant as it could provide a new treatment option for patients with relapsed or refractory multiple myeloma, a challenging and often fatal cancer. Approval could improve patient outcomes and quality of life. The move reflects ongoing advancements in cancer therapies and the importance of innovative treatments in oncology.

Implications

If approved, etentamig could change the treatment landscape for multiple myeloma, offering hope to patients who have exhausted other options. Healthcare providers may need to adapt treatment protocols and patient management strategies. The approval could also impact AbbVie’s market position and financial performance, as well as stimulate further research and development in bispecific antibody therapies.

What to watch

The FDA's timeline for reviewing the application will be critical, as it typically takes several months to reach a decision. Stakeholders will be monitoring any feedback from the FDA and potential advisory committee meetings. Additionally, the response from the medical community and patient advocacy groups regarding the trial results may influence public perception and support for the drug.